Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilretta, Synvisc One, and Monovisc for Knee Osteoarthritis
NCT05492851Phase 4Terminated
- Sponsor
- The Ohio State University
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of triamcinolone acetonide and sodium hyaluronate in knee osteoarthritis (OA) (3 arms), sponsored by The Ohio State University. Primary endpoint: Knee Injury and Osteoarthritis Outcome Score Pain Patient Reported Outcome Questionnaire at 5 months. Started Aug 2022; status: terminated.
02
Drugs
triamcinolone acetonidesodium hyaluronate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05492851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492851.